1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PAVmed Inc.
  6. News
  7. Summary
    PAVM   US70387R1068

PAVMED INC.

(PAVM)
  Report
Real-time Estimate Cboe BZX  -  05/25 01:38:52 pm EDT
0.9650 USD   -2.05%
05/16PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/13PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
BU
05/12PAVMED INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PAVmed Inc. and Lucid Diagnostics Inc. Appoint D.A. Wallace as Director, Retail Investor Relations

01/12/2022 | 08:25am EDT

PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. announced they have launched a new, full-time investor relations team to serve both companies. Adrian K. Miller has been appointed Vice President, Investor Relations, with broad strategic responsibilities across all aspects of investor communications, as well as a specific focus on institutional investors. D.A. Wallace has been appointed Director, Retail Investor Relations, working closely with Mr. Miller. Adrian Miller has over 20 years of experience in communications across the capital markets landscape. He most recently served as Director of Investor Relations and Chief Market Strategist at Concise Capital, where he was responsible for interacting with existing and potential investors to communicate investment strategy, cultivate a presence for the firm with reporters across financial media outlets, and distribute commentary to the investment media to help build the firm’s brand. Prior to that, Mr. Miller served as Chief Operating Officer of LM Capital Solutions, LLC, Director of Global Fixed Income Strategy at GMP Securities, and Director of Convertible and Credit Strategy at Citigroup. Mr. Miller received his undergraduate degree in Accounting and Finance from Widener University and serves as an adjunct professor at Fairleigh Dickinson University in the areas of finance, economics, and investing. D. A. Wallace brings over 20 years of institutional and retail investor relations experience, at companies including Home Depot and Cox Communications, First Data, ResCare, and The National Association of Investors Corp. Mr. Wallace is a former stockbroker and investment bank analyst.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION 1.60% 55.35 Delayed Quote.-19.76%
PAVMED INC. -2.18% 0.9605 Delayed Quote.-59.95%
All news about PAVMED INC.
05/16PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
05/13PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare ..
BU
05/12PAVMED INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Fin..
AQ
05/12PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Res..
BU
05/12PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12TRANSCRIPT : PAVmed Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/04Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study
PR
04/26PAVmed to Hold a Business Update Conference Call on May 12, 2022
BU
04/06PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
04/04PAVMED : Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinic..
PU
More news
Analyst Recommendations on PAVMED INC.
More recommendations
Financials (USD)
Sales 2022 2,88 M - -
Net income 2022 -76,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,12x
Yield 2022 -
Capitalization 86,7 M 86,7 M -
Capi. / Sales 2022 30,1x
Capi. / Sales 2023 5,40x
Nbr of Employees 89
Free-Float 89,7%
Chart PAVMED INC.
Duration : Period :
PAVmed Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PAVMED INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,99 $
Average target price 6,13 $
Spread / Average Target 522%
EPS Revisions
Managers and Directors
Lishan Aklog Chairman & Chief Executive Officer
Dennis M. McGrath President, Chief Financial Officer & Secretary
Brian J. deGuzman Chief Medical Officer & Executive Vice President
Shaun M. O’Neil Chief Operating Officer & Executive Vice President
Michael J. Glennon Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
PAVMED INC.-59.95%87
THERMO FISHER SCIENTIFIC-16.79%214 842
DANAHER CORPORATION-23.41%180 406
INTUITIVE SURGICAL, INC.-39.22%78 393
SIEMENS HEALTHINEERS AG-17.20%65 584
EDWARDS LIFESCIENCES CORPORATION-27.02%58 780